IMATINIB MESYLATE | NOVARTIS | ||
EQ 50MG BASE,EQ 100MG BASE | |||
No | No | ||
2022-Jun-19 | Expired | ||
None | None | ||
None | No | ||
Gleevec (imatinib mesylate) is indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
EQ 50MG BASE | ** | ** | - | - | - |
EQ 100MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com